Cancer Chemotherapy and Pharmacology
Overview
Cancer Chemotherapy and Pharmacology is a peer-reviewed journal that focuses on the latest advancements in the field of cancer treatment and pharmacology. It publishes original research articles, reviews, and clinical studies, covering various aspects of chemotherapy, drug development, pharmacokinetics, and pharmacodynamics. The journal aims to provide valuable insights into the efficacy, safety, and mechanisms of anticancer drugs, fostering the development of novel therapeutic strategies for cancer patients.
Details
Details
Metrics
Metrics
h-index / Ranks: 2180
122
SJR / Ranks: 4687
869
CiteScore / Ranks: 3626
6.20
JIF / Ranks: 3481
3.0
Recent Articles
11.
Cao A, Guan Y, Wang J, Li X, Liu S, Xuan Q, et al.
Cancer Chemother Pharmacol
. 2025 Feb;
95(1):33.
PMID: 39954071
Purpose: High-dose methotrexate (HD-MTX) is the cornerstone of the therapy for acute lymphoblastic leukemia (ALL). However, severe adverse events are frequently reported despite standard supportive cares. Therefore, we aim to...
12.
Balis F, Rieger E, Bunin N, Gardiner J, Shaw L, Olson T, et al.
Cancer Chemother Pharmacol
. 2025 Feb;
95(1):32.
PMID: 39932505
Purpose: Apply population pharmacokinetic modeling to a single institution busulfan therapeutic drug monitoring (TDM) data set from infants and children to refine dosing methods. Methods: One-compartment pharmacokinetic model was fit...
13.
Dai J, Cheng Y, Zhou Y, Wang Y, Liu Z, Ren Q, et al.
Cancer Chemother Pharmacol
. 2025 Feb;
95(1):31.
PMID: 39924599
Purpose: This study aims to investigate the effect of food intake on the pharmacokinetics of TQ05105 tablets in healthy Chinese subjects, and to evaluate the safety in these subjects. Methods:...
14.
Zhang H, Guo Y, Song Y, Shang C
Cancer Chemother Pharmacol
. 2025 Feb;
95(1):30.
PMID: 39899159
No abstract available.
15.
Funaishi K, Yamaguchi K, Tanahashi H, Kurose K, Sakamoto S, Horimasu Y, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):28.
PMID: 39853458
Background: The expression of anti-programmed cell death ligand-1 (PD-L1) in tumors is widely used as a biomarker to predict the therapeutic efficacy of anti-programmed cell death-1(PD-1)/PD-L1 antibodies. However, the predictive...
16.
Ri M, Iida S, Saito K, Saito Y, Maruyama D, Asano A, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):29.
PMID: 39853402
Purpose: A comprehensive analysis of metabolites (metabolomics) has been proposed as a new strategy for analyzing liquid biopsies and has been applied to identify biomarkers predicting clinical responses or adverse...
17.
Krishnamurthy A, Wang H, Rhee J, Davar D, Moy R, Ratner L, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):27.
PMID: 39841295
Background: ATR is an apical DDR kinase activated at damaged replication forks. Elimusertib is an oral ATR inhibitor and potentiates irinotecan in human colorectal cancer models. Methods: To establish dose...
18.
Shamaei Zadeh A, Roberts D, Williams A, Pandey D, Villano J
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):26.
PMID: 39825952
Purpose: Patients with partial or complete DPD deficiency have decreased capacity to degrade fluorouracil and are at risk of developing toxicity, which can be even life-threatening. Case: A 43-year-old man...
19.
Abegesah A, Oh D, Lim K, Fan C, Chen C, Kim C, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):23.
PMID: 39821700
Purpose: Durvalumab in combination with gemcitabine/cisplatin has shown a favorable benefit-risk profile in the TOPAZ-1 study for advanced biliary tract cancers (BTC). This analysis evaluated the population pharmacokinetics (PopPK) of...
20.
Maher K, Shafer D, Schaar D, Bandyopadhyay D, Deng X, Wright J, et al.
Cancer Chemother Pharmacol
. 2025 Jan;
95(1):24.
PMID: 39821392
Purpose: Relapsed and/or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome continue to have a poor prognosis with limited treatment options despite advancements in rational combination and targeted therapies. Belinostat...